Shares of Affymetrix ( AFFX) fell after a jury found that the company infringed an Oxford Gene Technology patent for analyzing genetic material. The company's shares resumed trading this afternoon after being halted, and were recently lower by $9.69, or 11.3%, to $76 in Nasdaq trading. The Delaware court ruled that there was "no literal or willful infringement" of the patent, but that there was infringement under the "doctrine of equivalents." Affymetrix said a second phase of the trial will consider the company's assertion that the Oxford Gene patent is invalid. Last week, shares of Affymetrix, which develops systems to analyze and manage genetic information, soared after a British appeals court found that the company's acquisition of a Beckman Coulter ( BEC) unit, which had a license for an Oxford patent, gave Affymetrix the right to use the technology.
More from Stocks
Google Secretly Gathering Medical Records on Millions of Patients, Report Says
Google teamed with hospital giant Ascension to secretly gather medical records on millions of patients across the country, the Wall Street Journal reports.
Market of the Week: Interest Rates vs. U.S. Stock Market
A phase one U.S.-China trade deal remains unsigned. Can it be completed by end of year?
Occidental Pete Falls on Report It's Seeking Bids for Some Anadarko Assets
The Houston energy company is seeking bids of as much as $700 million for Anadarko Petroleum properties in Wyoming and Colorado.
Interested in Alibaba? JD Looks Like a More Attractive Partner to Me
Fresh off the excitement of Singles Day, JD is the stock that appears a better play right now, as it's finding niche spots to fill in logistics and housing.